ReN 003

Drug Profile

ReN 003

Alternative Names: hRPC therapy - ReNeuron; ReN003

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard Medical School; ReNeuron; Schepens Eye Research Institute
  • Developer ReNeuron
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 08 Nov 2017 Phase-II clinical trials in Retinitis pigmentosa in USA (Subconjunctival) (NCT02464436)
  • 08 Nov 2017 Data Safety Monitoring Board (DSMB) approves progression of phase I/II trial in Retinitis pigmentosa to phase II portion before November 2017
  • 08 Nov 2017 ReNeuron plans a phase II trial for Retinitis pigmentosa in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top